Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs
Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...
405 Views
SEC and Drugmaker Allergan Reach Settlement over M&A Disclosure Violations
The U.S. Securities and Exchange Commission and drugmaker Allergan Plc (AGN US)Â settled claims that Allergan failed to disclose negotiations with...
511 Views
Cipla: Not the Best Among Peers but Catching up Fast, Keep on Watchlist.
Cipla Ltd (CIPLA IN) is India’s third largest pharmaceutical company. Cipla’s common stock is not the cheapest among peers, looking at the forward...
445 Views
Saroglitazar: Targeting Non-Alcoholic Steatohepatitis, a Potential US$35-40 Billion Market.
Nonalcoholic fatty liver disease (NAFLD), a disorder characterized by fatty changes (and fibrosis in later stages) is expected to affect about 20...
642 Views
Allergan's Wide Moat Supports Industry-Leading Growth and Profit
Innovative products, strong IP, and an unmatched aesthetics franchise drive Allergan's growth outlook. We anticipate high-single-digit growth for...
389 Views